Student Spotlight: Personalised Dosimetry for Radionuclide Therapy

IDH-genotype-linked kinase rewiring accompanies enhanced therapeutic response to dual-drug ferritin nanocages in high-grade glioma

Schietinger M. et al, (2026), Materials Today Bio, 40, 103539 - 103539

Zolbetuximab plus pembrolizumab and chemotherapy in CLDN18.2-positive, HER2-negative, PD-L1-positive gastric or gastroesophageal junction adenocarcinoma: randomized, double-blind, phase III LUCERNA trial

Shitara K. et al, (2026), ESMO Gastrointestinal Oncology, 13

Clinician and patient attitudes toward locoregional treatment of oligometastatic oesophago-gastric cancers: a mixed-methods study

Lakha AS. et al, (2026), ESMO Gastrointestinal Oncology, 13

Can GLP-1RA be utilised for pre-operative liver optimisation prior to hepatectomy? A scoping review of MASLD evidence with surgical translation

Vaitha R. et al, (2026), Clinical Surgical Oncology, 5, 100136 - 100136

pysigscore: gene signatures scoring across bulk and single-cell transcriptomics

Giacomello T. et al, (2026)

Context-dependent efficacy of fibroblast activation protein-targeted radionuclide therapy (FAP-TRT): the dual role of CAFs.

Wu C. et al, (2026), Eur J Nucl Med Mol Imaging

Nucleophagy as an emerging therapeutic vulnerability in cancer.

Tribble S. and Ramadan K., (2026), Autophagy, 1 - 3

Oncology drug development in the UK: analysis of the past 25 years and focus on the 2026 reboot of the clinical trial regulatory framework.

Czajka-Francuz P. et al, (2026), Br J Cancer

Mitochondrial metabolism determines chemotherapy sensitivity in colorectal cancer.

Moss DY. et al, (2026), Nat Metab

Evidence of endothelial anergy and T-cell exclusion in microsatellite stable colorectal liver metastases revealed through human hemi-liver perfusion and spatial transcriptomics.

Wan PK-T. et al, (2026), Mol Cancer

The FAIR Case for A Coherent Interoperability to support NHS 10 Year Health Plan.

Tomlinson H. et al, (2026), Sci Data

Preclinical characterization and phase 1 clinical testing of targeting mitochondrial peroxiredoxin 3 in cancer.

Gibson V. et al, (2026), Nat Commun, 17

Down-Regulation of Proline Rich Homeodomain/Haematopoietically Expressed Homeobox Expression in Prostate Cells Enables Tumour Initiation and Tumour Growth.

Marcolino E. et al, (2026), Cancers (Basel), 18

The pharmacological profile of ART6043, a first-in-class clinical DNA polymerase theta polymerase domain inhibitor potentiating PARP inhibitor efficacy.

Robinson HMR. et al, (2026), Clin Cancer Res

Benefit of adjuvant chemotherapy for resected pancreatic cancer following neoadjuvant FOLFIRINOX or Gemcitabine-Nab-paclitaxel: a multinational analysis.

Lopez-Lopez V. et al, (2026), J Natl Cancer Inst

Antibody-drug conjugates in selected solid tumours: a position statement update based on findings from the third workshop held by the ETOP IBCSG Partners Foundation.

Peters S. et al, (2026), ESMO Open, 11

Tirapazamine sensitises hypoxic homologous recombination-proficient NSCLC to PARP inhibition.

Jiang Y. et al, (2026), Cell Death Discov

Forging New Pathways in Oncology: Strategic Insights from the 17th Annual Frontiers in Cancer Science Conference.

Huang D. et al, (2026), Cancer Res, 86, 3106 - 3108

CDIN1-Codanin-1 complex defective in congenital dyserythropoietic anaemia type I is an RNA nuclease.

Brolih S. et al, (2026), Nat Commun

Addition of rituximab to first-line treatment of Burkitt lymphoma in children and young adults in Tanzania: a cost-utility analysis

MORRELL L. et al, (2026), Journal of Clinical Oncology Global Oncology

Search results

Showing results for